{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:42:09Z","timestamp":1787960529353,"version":"build-2784847793"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. This open-label extension (OLE) trial evaluated the long-term effects of etelcalcetide for sHPT treatment in patients receiving hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This 52-week, multicenter, single-arm OLE enrolled patients from three parent trials: two randomized, double-blind, placebo-controlled trials and one open-label, single-arm, \u2018switch\u2019 study from cinacalcet to etelcalcetide. The primary endpoint was to investigate the nature, frequency, severity and relation to treatment of all adverse events (AEs) reported throughout the trial. Secondary endpoints included the proportion of patients with &amp;gt;30% reduction from baseline in PTH and the percentage change from baseline in PTH, albumin-corrected calcium (Ca), phosphate (P) and the calcium\u2013phosphate product (Ca\u2009\u00d7\u2009P).<\/jats:p>\n                    <jats:p>ClinicalTrials.gov identifier: NCT01785875; Amgen study: 20120231.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 89.8% of the patients experienced one or more treatment-emergent AE. The most common were decreased blood Ca (43.3%), diarrhea (10.8%), vomiting (10.4%) and nausea (9.6%); symptomatic hypocalcemia occurred in 3.7% of the patients. Approximately 68% of patients achieved &amp;gt;30% reduction in PTH, and \u223c56% achieved PTH \u2264300\u2009pg\/mL. Mean percent changes from baseline ranged from \u221225.4% to \u221226.1% for PTH, \u22128.3% to \u22129.1% for Ca, \u22123.6% to \u22124.1% for P and \u221212.0% to \u221212.6% for Ca\u2009\u00d7\u2009P.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Etelcalcetide effectively lowered PTH and its effect was sustained, while no new safety concerns emerged over a 1-year treatment period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfz039","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T23:13:59Z","timestamp":1549408439000},"page":"1769-1778","source":"Crossref","is-referenced-by-count":29,"title":["One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism"],"prefix":"10.1093","volume":"35","author":[{"given":"David A","family":"Bushinsky","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University of Rochester School of Medicine, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M","family":"Chertow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Stanford University, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Deng","sequence":"additional","affiliation":[{"name":"Biostatistics, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Kopyt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Lehigh Valley Hospital, Allentown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Saint Louis University School of Medicine, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University of California, Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Ramsay-G\u00e9n\u00e9rale de Sant\u00e9, Clinique du Landy, Saint Ouen, France and Necker Hospital, University of Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-9415","authenticated-orcid":false,"given":"Marc","family":"Vervloet","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Amsterdam Cardiovascular Sciences, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A","family":"Block","sequence":"additional","affiliation":[{"name":"Denver Nephrology, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"2020100618541729500_gfz039-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"2020100618541729500_gfz039-B2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"2020100618541729500_gfz039-B4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","article-title":"Chronic kidney disease and its complications","volume":"35","author":"Thomas","year":"2008","journal-title":"Prim Care"},{"key":"2020100618541729500_gfz039-B5","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1097\/01.ASN.0000034202.91413.EB","article-title":"The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease","volume":"13","author":"De Boer","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2020100618541729500_gfz039-B7","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ackd.2006.10.010","article-title":"Bone health in chronic kidney disease-mineral and bone disease","volume":"14","author":"Gal-Moscovici","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"2020100618541729500_gfz039-B9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2020100618541729500_gfz039-B10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"2020100618541729500_gfz039-B12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpneph0977","article-title":"Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?","volume":"5","author":"Wetmore","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"2020100618541729500_gfz039-B14","first-page":"i18","article-title":"Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin D sterols in dialysis patients","volume":"1","author":"Bushinsky","year":"2008","journal-title":"NDT Plus"},{"key":"2020100618541729500_gfz039-B15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/sdi.12446","article-title":"Vitamin D and clinical outcomes in dialysis","volume":"28","author":"Parikh","year":"2015","journal-title":"Semin Dial"},{"key":"2020100618541729500_gfz039-B16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nefro.2015.10.006","article-title":"Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism","volume":"36","author":"de Francisco","year":"2016","journal-title":"Nefrologia"},{"key":"2020100618541729500_gfz039-B17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-015-0174-6","article-title":"Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design","volume":"16","author":"Reams","year":"2015","journal-title":"BMC Nephrol"},{"key":"2020100618541729500_gfz039-B18","volume-title":"Full Prescribing Information","year":"2017"},{"key":"2020100618541729500_gfz039-B19","volume-title":"Summary of Product Characteristics","year":"2017"},{"key":"2020100618541729500_gfz039-B20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"},{"key":"2020100618541729500_gfz039-B21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.110.178194","article-title":"Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor","volume":"337","author":"Ma","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2020100618541729500_gfz039-B22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2020100618541729500_gfz039-B23","article-title":"Initiation of AMG 416 after discontinuation of cinacalcet","volume":"26","author":"Liss","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2020100618541729500_gfz039-B25","author":"Block","year":"2017"},{"key":"2020100618541729500_gfz039-B26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s10157-017-1442-5","article-title":"Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism","volume":"22","author":"Shigematsu","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2020100618541729500_gfz039-B27","volume-title":"Full Prescribing Information","year":"2017"},{"key":"2020100618541729500_gfz039-B28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1091581816633407","article-title":"Nonclinical safety profile of etelcalcetide, a novel peptide calcimimetic for the treatment of secondary hyperparathyroidism","volume":"35","author":"Fielden","year":"2016","journal-title":"Int J Toxicol"},{"key":"2020100618541729500_gfz039-B29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.kint.2017.12.014","article-title":"Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial","volume":"93","author":"Floege","year":"2018","journal-title":"Kidney Int"},{"key":"2020100618541729500_gfz039-B30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US commentary on the 2017 KDIGO Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2020100618541729500_gfz039-B31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semnephrol.2018.02.005","article-title":"Vitamin D and calcimimetics in cardiovascular disease","volume":"38","author":"Lim","year":"2018","journal-title":"Semin Nephrol"},{"key":"2020100618541729500_gfz039-B33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2020100618541729500_gfz039-B34","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2020100618541729500_gfz039-B35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2017.03.005","article-title":"Clinical immunogenicity of the D-amino acid peptide therapeutic etelcalcetide: method development challenges and anti-drug antibody clinical impact assessments","volume":"445","author":"Kroenke","year":"2017","journal-title":"J Immunol Methods"},{"key":"2020100618541729500_gfz039-B36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing antibody: biotherapeutic modality-based review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS J"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/10\/1769\/33840207\/gfz039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/10\/1769\/33840207\/gfz039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:54:35Z","timestamp":1602010475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/10\/1769\/5374826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,3,11]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz039","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735312114.793577513","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2019,3,11]]}}}